Ivermectin, Fenbendazole and Mebendazole Cancer Protocol in Cancer (2024–2026): Evidence, Safety, and Real-World Outcomes

By Editorial Team

Review Summary (Updated April 2026)

This page reviews the 2024 hybrid orthomolecular cancer protocol published in the Journal of Orthomolecular Medicine (Baghli, Martinez et al., Sept 2024). The protocol combines repurposed antiparasitic drugs, metabolic therapies, and nutritional interventions to target cancer through the proposed mitochondrial-stem cell connection (MSCC).

The approach integrates:

  • Antiparasitics: ivermectin + benzimidazoles (mebendazole/fenbendazole)

  • Metabolic therapies: ketogenic diet, fasting strategies

  • High-dose micronutrients: vitamin C, vitamin D, zinc

  • Adjunct lifestyle and supportive therapies

It is positioned as a complementary (not alternative) strategy alongside standard oncology care.

Key Mechanisms (Simplified)

The protocol is based on multi-targeted anti-cancer effects observed in preclinical studies:

  • Microtubule disruption: Benzimidazoles interfere with cancer cell division

  • Metabolic targeting: Restricts glucose/glutamine pathways (Warburg effect)

  • Cancer stem cell (CSC) impact: Potential reduction in recurrence drivers

  • Apoptosis induction: Promotes programmed cancer cell death

  • Anti-angiogenesis: May reduce tumor blood supply

📊 Evidence Level: What the Science Actually Says (2026 Update)

⚠️ Current Consensus

  • Most evidence for ivermectin and fenbendazole/mebendazole is preclinical (lab + animal studies)

  • Human data remains limited and heterogeneous

  • Major institutions like the National Cancer Institute emphasize that these are not proven cancer treatments.

Self-reported cancer outcomes at 6-month follow-up (N=122)

Clinical Data Snapshot

  • One positive phase 2 RCT using mebendazole in colorectal cancer (Life Sciences 2022).

  • Early-phase ivermectin + immunotherapy trials show limited but suggestive activity

  • Case reports and anecdotal recoveries remain hypothesis-generating, not definitive (One Day MD 2026)

👉 Bottom line: Promising—but not yet validated by large randomized trials

NEW: 2026 Real-World Observational Study

2026 Cohort: Ivermectin + Mebendazole Combination

A prospective observational study (Hulscher et al., April 2026) evaluated:

  • 197 total patients

  • 122 with ≥6 months follow-up

Reported Outcomes:

  • 84.4% Clinical Benefit Rate (CBR)

    • 32.8%: No Evidence of Disease (NED)

    • 15.6%: Tumor regression

    • 36.1%: Stable disease

Safety:

  • 25.4% reported mild gastrointestinal side effects

  • Most patients continued treatment

Important Context:

  • Mixed cancer types (breast, prostate, colorectal, etc.)

  • Many patients also used:

    • Conventional treatments

    • Diet/lifestyle interventions

⚠️ Limitations:

  • Observational (not randomized)

  • Self-reported outcomes

  • Potential selection bias

  • No control group

👉 Interpretation: Largest real-world dataset to date—but still hypothesis-generating

🧪 Fenbendazole vs Mebendazole: Critical Differences

  • Mebendazole

    • Human-approved antiparasitic

    • Some clinical oncology data exists

  • Fenbendazole

    • Veterinary drug (not FDA-approved for humans)

    • Limited human evidence

    • Preclinical studies show:

      • Glycolysis inhibition

      • Pyroptosis activation

Read More: Fenbendazole vs Mebendazole for Cancer: What is the Difference?

Safety, Monitoring, and Medical Supervision

While generally described as well-tolerated in studies, key risks include:

  • Liver enzyme elevation

  • Drug interactions

  • Unknown long-term effects in cancer dosing

Essential Monitoring:

  • Liver function tests (LFTs)

  • Full blood count

  • Clinical response tracking

👉 Strong recommendation: Work with a qualified physician, ideally via organizations like the Society for Integrative Oncology

⚖️ Balanced Medical Perspective

Mainstream oncology bodies emphasize:

  • These therapies are not FDA-approved for cancer

  • Should not replace standard treatments (chemotherapy, immunotherapy, surgery)

  • Delaying proven care may worsen outcomes

At the same time:

  • Research interest is growing

  • Repurposed drugs offer low-cost global accessibility potential.


Final Verdict

The hybrid orthomolecular protocol represents a high-interest, emerging integrative approach with:

✅ Strong biological rationale
✅ Growing real-world signals
❌ Limited high-quality human trial evidence

👉 Best use case today: As a physician-guided complementary strategy, not a replacement for standard care.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

Archive

Show more